Taysha Gene Therapies
TSHA
4.43
+0.04
+0.91%
Taysha Gene Therapies
US · TSHA
#3015 by market cap
Listed 2020
4.43
+0.04
+0.91%
Live - 5344 symbols - heartbeat 90s ago
· 2026-10-08 04:03
Pre-market
4.41
-0.45%
After-hours
4.43
0.00%
- Market cap
- 1.44B
- P/E (TTM)i
- -10.80
- P/Bi
- 3.73
- EPSi
- -0.34
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on TSHA?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 7 years
Margins
- Operating margin
- -1,130.65%
- Net margin
- -1,115.27%
Key ratios & quality
- Enterprise valuei
- 1.18B
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | -- | -- | 0 | 2.50M | 15.45M | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | -- | 11.11M | 41.32M | 37.36M | 30.05M | 28.95M | 33.87M |
| Research & development | -- | 31.89M | 131.94M | 91.17M | 56.78M | 66.00M | 86.40M |
| Operating profit | -- | -43.00M | -173.27M | -126.03M | -71.37M | -86.62M | -110.50M |
| Pretax profit | -- | -60.01M | -174.52M | -166.01M | -111.57M | -89.30M | -109.00M |
| Tax | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -- | -60.01M | -174.52M | -166.01M | -111.57M | -89.30M | -109.00M |
| Basic EPS | -- | -3 | -5 | -4 | -1 | 0 | 0 |
| Diluted EPS | -- | -3.40 | -4.64 | -3.78 | -0.96 | -0.36 | -0.34 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.30M | 1.99M | 0 | -- | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 8.16M | 8.60M | 8.28M | 8.83M | 9.68M | 12.15M |
| Research & development | 15.57M | 20.14M | 25.75M | 24.95M | 33.81M | 38.64M |
| Operating profit | -21.42M | -26.75M | -34.02M | -28.30M | -43.49M | -50.78M |
| Pretax profit | -21.53M | -26.88M | -32.73M | -27.85M | -42.41M | -46.64M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -21.53M | -26.88M | -32.73M | -27.85M | -42.41M | -46.64M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.08 | -0.09 | -0.09 | -0.08 | -0.12 | -0.13 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 15.00K | 257.88M | 159.60M | 96.42M | 149.87M | 142.13M | 324.65M |
| Cash & ST investments | 0 | 251.25M | 149.10M | 87.88M | 143.94M | 139.04M | 319.77M |
| Inventory | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 15.00K | 258.88M | 213.96M | 126.28M | 172.73M | 160.36M | 343.32M |
| Total current liabilities | 150.00K | 7.13M | 51.75M | 62.79M | 36.76M | 26.23M | 26.55M |
| Short-term debt | -- | -- | -- | 1.52M | 1.65M | 1.88M | 1.87M |
| Long-term debt | -- | -- | 37.19M | 37.97M | 40.51M | 43.94M | 50.11M |
| Total liabilities | 150,000.00 | 7,579,000.00 | 118,573,000.00 | 125,327,000.00 | 97,794,000.00 | 88,839,000.00 | 96,382,000.00 |
| Total equity | -135.00K | 251.30M | 95.38M | 949.00K | 74.94M | 71.53M | 246.94M |
| Retained earnings | -1.12M | -61.13M | -235.65M | -401.44M | -513.01M | -602.31M | -711.30M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 120.71M | 316.26M | 299.95M | 324.65M | 282.25M | 461.43M |
| Cash & ST investments | 116.59M | 312.76M | 297.34M | 319.77M | 276.58M | 455.41M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 138.36M | 333.33M | 316.55M | 343.32M | 300.35M | 470.43M |
| Total current liabilities | 22.56M | 25.35M | 28.63M | 26.55M | 20.10M | 25.98M |
| Short-term debt | 1.81M | 1.74M | 1.67M | 1.87M | 1.82M | 1.16M |
| Long-term debt | 42.45M | 41.05M | 50.85M | 50.11M | 48.96M | 49.26M |
| Total liabilities | 83,303,000.00 | 84,604,000.00 | 97,565,000.00 | 96,382,000.00 | 88,407,000.00 | 83,167,000.00 |
| Total equity | 55.06M | 248.73M | 218.99M | 246.94M | 211.94M | 387.27M |
| Retained earnings | -623.83M | -650.72M | -683.45M | -711.30M | -753.71M | -800.35M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -- | -30.73M | -117.04M | -88.39M | -73.02M | -81.23M | -93.09M |
| Depreciation & amortization | -- | 9.00K | 492.00K | 1.17M | 1.37M | 1.25M | 1.15M |
| Free cash flow | -- | -39.81M | -138.60M | -113.26M | -80.39M | -81.60M | -93.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 165.85M | 0 | 53.24M | 140.79M | 76.78M | 264.31M |
| Ending cash balance | -- | 251.25M | 151.74M | 90.52M | 146.54M | 141.64M | 322.53M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -22.02M | -20.18M | -24.17M | -26.72M | -40.88M | -40.43M |
| Depreciation & amortization | 283.00K | 277.00K | 286.00K | 299.00K | 295.00K | 291.00K |
| Free cash flow | -22.40M | -20.18M | -24.27M | -26.97M | -43.90M | -40.42M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -454.00K | 48.59M | -- | -- |
| Ending cash balance | 119.19M | 315.36M | 299.94M | 322.53M | 279.34M | 455.57M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -47.79 | -100.68 | -344.67 | -294.04 | -121.94 | -68.45 |
| ROA %i | -- | -46.36 | -73.82 | -97.59 | -74.62 | -53.62 | -43.28 |
| ROIC %i | -- | -47.80 | -73.28 | -147.11 | -111.86 | -71.01 | -52.31 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -181.82 | -185.96 |
| EBIT margin %i | -- | -- | -- | -6,483.45 | -689.72 | -1,070.39 | -1,114.62 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.10 | 36.17 | 3.08 | 1.54 | 4.08 | 5.42 | 12.23 |
| Quick ratioi | -- | 35.24 | 2.88 | 1.40 | 3.92 | 5.30 | 12.04 |
| Debt / assetsi | -- | 0.00 | 29.49 | 47.46 | 35.38 | 39.40 | 20.43 |
| LT debt / equityi | -- | -- | 66.15 | 6,154.58 | 79.35 | 85.71 | 27.65 |
| Interest coveragei | -- | -2,142.25 | -121.21 | -42.71 | -21.32 | -874.47 | -1,729.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 57.49 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -159.34 | -51.86 | -64.93 | -68.45 | -97.28 | -47.05 |
| ROA %i | -59.56 | -34.74 | -40.23 | -43.28 | -59.21 | -37.23 |
| ROIC %i | -80.74 | -41.96 | -49.12 | -52.31 | -70.70 | -42.68 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,199.81 | -1,143.96 | -1,582.50 | -1,114.62 | -1,737.69 | -2,727.27 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.35 | 12.48 | 10.48 | 12.23 | 14.04 | 17.76 |
| Quick ratioi | 5.17 | 12.34 | 10.39 | 12.04 | 13.76 | 17.53 |
| Debt / assetsi | 44.34 | 17.88 | 21.81 | 20.43 | 22.82 | 12.06 |
| LT debt / equityi | 108.15 | 23.26 | 30.76 | 27.65 | 31.48 | 14.34 |
| Interest coveragei | -942.11 | -1,129.73 | -1,367.89 | -1,729.08 | -2,449.49 | -3,561.69 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Gene therapy segment100.00%
Region
United States100.00%
Quote time 2026-10-08 04:03:15 · For reference only, not investment advice and not tailored to your situation.